Objective: Increased immunoreactivity of integrin-linked kinase (ILK) in the primary tumour is an adverse prognostic factor in a variety of preclinical and clinical models of human cancer. Here, we investigate the relationship between ILK immunoreactivity in primary non-small-cell lung cancer (NSCLC) and the survival after curative lung resection. Methods: Tumour specimens of 138 radically operated NSCLC patients have been retrieved from the pathology archive, mounted in tissue microarrays and immunostained against ILK. The immunoreactivity against ILK has been graded in a semi-quantitative manner (negative or 1-3 positive) by two observers blinded to any patient data, and correlated to the survival data. Results: In total, 88 of 138 tumours (64%) showed an ILK immunoreactivity, which varied significantly between various histological subtypes as it ranged from 46% (squamous cell carcinoma (SCC)) to 79% (adenocarcinoma) ( p = 0.019). The 5-year cancer-related survival of ILK-positive SCC patients was at 42 AE 10% versus 72 AE 9% significantly shorter than in ILK-negative patients ( p = 0.011). In addition, the recurrence-free survival (RFS) of ILK-positive SCC patients was also significantly shorter than of ILK-negative patients (38 AE 10% vs 60 AE 10%) ( p = 0.005). In multivariate analysis, ILK expression was a significant prognostic factor for RFS in squamous cell carcinoma ( p = 0.018), but not in adenocarcinoma or in the rare histology group. Conclusions: Primary NSCLC tumours show a variable ILK immunoreactivity, dependent on the histological subtype. In SCC, ILK immunoreactivity is a significantly adverse prognostic factor. #
Introduction
Lung cancer is the leading cause of cancer death in the Western world. The overall survival across stages is around 14% at 5 years; [1] at first presentation, a major proportion of patients is already in a progressed stage of disease. In addition, a considerable percentage of even early-stage nonsmall-cell lung cancer (NSCLC) patients suffer from recurrence after curative resection, suggesting that the individual prognosis cannot be sufficiently predicted by conventional staging alone.
The biological process of local and systemic tumour progression consists of several steps: detachment of single tumour cells from the primary tumour, invasion via conducting structures (blood and lymph vessels), docking and homing in on the target region and establishment of a sufficient nutrient supply. Cell adhesion molecules play an important role in the whole process; thus, all five classes of cell adhesion molecules (CAMs) -integrins, cadherins, immunoglobulin-like CAMs, selectins and CD44s -are characteristically dysregulated in human cancer [2] . Of the above CAMs, integrins are most relevant to NSCLC biology [3] . Altered integrin expression was reported to be a poor prognostic factor in NSCLC [4] [5] [6] .
The functional link between integrins and the downstream intracellular pathways is apparently given by the recently described integrin-linked kinase (ILK) [7] , which colocalises with the cytoplasmic tail of b1-integrins. ILK activity is constitutively activated in phosphatase and tensin homologue (PTEN)-negative tumours, and inhibiting ILK induces apoptosis and cell-cycle arrest. ILK regulates tumour angiogenesis; ILK activation promotes vascular endothelial growth factor (VEGF) expression in tumour cells, and ILK has an essential role in VEGF-mediated endothelial activation and angiogenesis [8] . ILK expression and activity are increased in many types of cancer, such as prostate, colon, gastric and ovarian cancers, malignant melanomas (for a summary see Hannigan and co-workers [9] ), malignant pleural mesothelioma [10] and NSCLC [11, 12] . Smallmolecule inhibitors of ILK have been identified and shown to inhibit cancer-cell growth, survival and invasion in vitro and tumour growth and angiogenesis in vivo [9, 13, 14] .
The prognostic relevance of ILK in NSCLC has for the first time been shown in two recent studies investigating ILK expression in Asian patients [11, 12] . In detail, in a retrospective clinico-pathological study involving 134 NSCLC patients, Takanami and co-workers reported a significantly reduced 5-year survival rate for patients with ILK expression in the primary tumour [12] . In another series of 118 Asian NSCLC patients, Okamura and co-workers provided evidence that ILK, integrin b1 and phosphorylated Akt (Ser 473; pAkt) are mutually associated with poor prognosis [11] .
However, since the ethnical background has been identified as an important prognostic co-factor in NSCLC [15] , caution is advised in translating molecular biological findings into other ethnicities. In this study, we analyse ILK immunoreactivity in the primary tumour of 138 Caucasian NSCLC patients, and correlate ILK immunoreactivity with survival after curative resection.
Material and methods
Our cohort consisted of 138 Caucasian patients who underwent curative surgery for NSCLC between 1998 and 2002 at our institution, and who have been followed up since then for recurrence. All patients with pneumonectomy and all patients with either insufficient specimens or incomplete follow-up had been excluded. Our follow-up policy determined a chest computed tomography (CT) scan every 3 months in first year after surgery, every 6 months in the second year and once a year thereafter. For assessment of the disease state, the attending physician's notes have been evaluated. If the patient was free of recurrence at his/her last visit, the subsequent death has been considered cancerunrelated. Conversely, if the patient had clinical and/or radiological signs of tumour presence at his/her last visit, the subsequent death has been ascribed to the tumour.
The median (range) follow-up was 5.7 (0-10 years) years. The median (range) age at diagnosis was 61 (39-81 years) years. The most prevalent histological subtype was adenocarcinoma (51%). The majority of cases were in pathological stage IB (30%); the stages were equally distributed amongst histological subtypes (Table 1) . Only a very small number of patients had chemotherapy (four patients with induction chemotherapy; two patients with adjuvant chemotherapy).
For the histopathological work-up, tissue cores from viable tumour areas as identified by haematoxylin-eosin stained slides were selected to construct tissue microarrays; one tissue core of 2 mm was taken from each tumour block. For subsequent immunohistochemistry, 2-mm sections of tissue microarrays were used. The staining procedure was performed in an automated slide stainer (Benchmark, Ventana, Tucson, AZ, USA). Antigen retrieval was done by heating in the stainer.
The commercially available polyclonal rabbit anti-ILK antibodies (MBL International Corp., Woburn, MA, USA) were used at 1:25 dilution with overnight incubation at 4 8C. For detection of binding sites, a streptavidin-biotin system was used. Visualisation was achieved with FastRed chromogen. Because, consistently, no more than 10% of tumour cells were ILK-positive, a calculation of ILK scores as described by Okamura and co-workers [11] has not been employed. The intensity of ILK immunoreactivity was evaluated as follows: 0, no immunoreactivity; 1, weak immunoreactivity; 2, medium immunoreactivity; and 3, strong immunoreactivity. Subsequently, we compared the intensity of ILK immunoreactivity with clinical parameters.
End points of the clinical analysis were: cancer-related survival, recurrence-free survival (RFS), incidence of local recurrence, incidence of distant recurrence and incidence of cancer-unrelated death. Cancer-related survival was defined as the time from surgery to death from cancer or last followup with cancer. RFS was defined as the time from surgery to recurrence or to cancer-unrelated death. Cancer-related survival and RFS were estimated with the Kaplan-Meier method [16] with the Greenwood formula for estimation of standard errors. Local recurrence was defined as any recurrence within the ipsilateral hemithorax and the mediastinum. All other types of recurrence were classified as distant recurrence.
The degree of ILK immunoreactivity in different histological subtypes was compared by cross-table analysis. The influence of ILK expression on cancer-related survival and RFS has been assessed with the log-rank method. A Cox proportional hazard model was used to study the impact of ILK adjusted for the other potential predictors (histology). All summary statistics were presented as median for continuous variables and as percentage for categorical variables. Results were considered to be significant at p < 0.05. All calculations have been performed using the SAS W software package. 
Results
In total, 88 of 138 tumours (64%) showed an ILK immunoreactivity; 30/88 (34%) ILK-positive samples showed a strong or medium ILK immunoreactivity. The overall intensity of ILK immunoreactivity varied significantly between various histological subtypes as it ranged from 46% (squamous cell carcinoma (SCC)) to 79% (adenocarcinoma) ( p = 0.019) ( Table 2 ). ILK immunoreactivity was not correlated with age, sex, tumour grade, T factor, N factor or stage (data not shown). Morphologically, ILK was detected in the cytoplasm of tumour cells, as well as in tumour stromal cells and tumour-infiltrating lymphocytes. Interestingly, we observed a much stronger ILK immunoreactivity in tumour stromal cells of SCC as compared with tumour stromal cells in adenocarcinomas (Fig. 1) . In non-neoplastic lung tissue, ILK was detected focally in endothelial cells, in vascular smooth muscle cells, in bronchial glands and in the cytoplasm of bronchial epithelial cells.
The 5-year cancer-related survival of ILK-positive SCC patients was at 42 AE 10% versus 72 AE 9% significantly shorter than the cancer-related survival of ILK-negative patients ( p = 0.011). Conversely, there was no significant difference in 5-year cancer-related survival of ILK-negative and ILK-positive adenocarcinoma patients (Fig. 2) . The RFS of ILK-positive SCC patients was significantly shorter than the RFS of ILK-negative patients (38 AE 10% vs 60 AE 10%) ( p = 0.005). Again, there was no significant difference of RFS in ILK-negative and positive adenocarcinoma patients (Fig. 3) .
The 5-year cumulative incidence of local and distant recurrence was similar in ILK-negative and positive SCC patients. However, in ILK-positive adenocarcinoma patients, the 5-year cumulative incidence of local recurrence was much lower ( p = 0.004). Regarding distant recurrence, similar to SCC, there was no difference between ILK-negative and positive cases (Table 3) . Furthermore, ILK-positive SCC patients had a two times higher 5-year incidence of cancerunrelated deaths, as compared with ILK-negative patients (25 AE 9% vs 12 AE 6%) ( p = 0.018); this was not seen in the group of adenocarcinoma patients (Table 4) .
Performing a multivariate analysis adjusted for histological subtype, T factor and N factor, ILK immunoreactivity was an almost significant prognostic factor for 5-year cancerrelated survival in SCC ( p = 0.057) and in the rare histology group ( p = 0.048), but not in adenocarcinoma. Regarding RFS, ILK immunoreactivity was a significant prognostic factor in SCC ( p = 0.018), but not in adenocarcinoma or in the rare histology group (Table 5 ).
Discussion
In this study, we report that primary NSCLC tumours in Caucasians show an ILK immunoreactivity in 46-79% of cases, dependent on the histological subtype, and that ILK immunoreactivity is associated with reduced cancer-related survival and RFS in the SCC subtype. These data are only partially comparable to the findings in Asian patients [11, 12] .
First, in contrast to the previously published reports, the immunoreactivity of ILK was significantly dependent on the histological subtype with adenocarcinomas having the highest and SCC having the lowest percentage of ILK immunoreactivity. There were also morphological differences: tumour stromal cells of SCC reacted stronger for ILK than tumour stromal cells in adenocarcinomas. In addition, while in Takanami's series [12] , ILK immunoreactivity was not seen in Table 3 ILK immunoreactivity and patterns of recurrence, stratified by histological subgroups. Table 4 ILK immunoreactivity in the primary tumor and the 5-year incidence of cancerunrelated deaths. epithelial cells in normal lung tissue, in our series ILK was detected focally in the cytoplasm of bronchial epithelial cells outside the tumour. Our data provide evidence that ILK immunoreactivity in SCC is associated not only with decreased cancer-related survival, but also with decreased cancer-unrelated survival. We have no explanation for this observation, at least no explanation based on hard data. Besides the conclusion, that ILK plays no context-independent role in the biology of NSCLC, our data should prompt a different, more systemic view on tumour progression and survival after curative lung cancer resection. One of the strengths of our study lies in the fact that, in most of our fatal cases, we were able to obtain information about the cause of death showing that the subgroup of patients, which is most affected by tumour progression, does also suffer from a higher rate of noncancer-related deaths. Thus, ILK-positive patients have apparently not only a faster tumour progression, but also a higher co-morbidity.
To explain this phenomenon, it might be useful to take a look at the ILK immunoreactivity of tumour stromal cells and of tumour-infiltrating lymphocytes. There is increasing evidence that ILK function is required for inflammatory responses [17] [18] [19] . In addition, there is also both in vitro [20] and in vivo [21, 22] evidence on the importance of inflammatory responses in lung carcinogenesis. Furthermore, the increased expression of ILK in vascular smooth muscle cells has also been linked to the genesis of atherosclerosis [23, 24] . Thus, we speculate that strong ILK expression, as seen in SCCs, may be part of a systemic ILK up-regulation, causing a systemic inflammatory response, which promotes both carcinogenesis and atherosclerosis. However, we strongly suggest that further studies on ILK biology take into account not only local and organ-specific but also systemic alterations of ILK expression. In addition, in future prognostic studies about NSCLC, the influence of comorbidity on cancer-related survival should be taken more seriously into consideration.
The limitations of our study are the retrospective design, and also the fact that the results are based on tissue microarrays. In a recent report, Bibeau and co-workers [25] compared the correlation of epidermal growth factor receptor (EGFR) expression in primary and metastatic colorectal tumour as assessed either by conventional tissue section or by tissue microarray. Interestingly, by conventional technique, the concordance rate was 78%, while by tissue microarray the concordance rate dropped to 43%. On the other hand, the use of tissue microarrays minimises the variability of the staining process.
We conclude that Caucasians show ILK immunoreactivity to a varying degree in the primary NSCLC tumour, and that ILK immunoreactivity is an adverse prognostic factor in the squamous cell carcinoma subgroup.
